A planned interim analysis of 775 patients in Merck’s study found that 7.3% of those given molnupiravir were either hospitalized or had died by 29 days after treatment, compared with 14.1% of placebo patients. There were no deaths in the molnupiravir group, but there were eight deaths of placebo patients.
Merck to Seek FDA OK for Its COVID Pill After Trial Stopped Early — https://www.medscape.com/viewarticle/960089?src=rss#vp_2
- Comment
- Reblog
-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
lifeunderwriter.net 
I guess this is good news? Were any of the people treated vaccinated? Will people unwilling to receive a vaccination be willing to take a new medication? Maybe so, since at least in Florida they’re flocking to the monoclonal antibodies provided by governor Death-santis.
https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
Potentially good news. My other reply is a link to the Merck press release. The answer to your second question is not directly addressed in the presser. The answer to your third question is in my opinion, probably no
They’ll probably still want to stick with hydroxychloroquine and ivermectin. People around here are still taking them. Shaking my head…
The situation has gotten worse. Hydrogen peroxide in a nebulizer!